Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Cash (2020 - 2025)

Historic Change in Cash for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$12.1 million.

  • Barinthus Biotherapeutics' Change in Cash fell 375.26% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.4 million, marking a year-over-year increase of 4386.7%. This contributed to the annual value of -$29.7 million for FY2024, which is 4322.59% up from last year.
  • Barinthus Biotherapeutics' Change in Cash amounted to -$12.1 million in Q3 2025, which was down 375.26% from -$12.8 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' Change in Cash's 5-year high stood at $112.7 million during Q1 2021, with a 5-year trough of -$19.8 million in Q4 2021.
  • For the 5-year period, Barinthus Biotherapeutics' Change in Cash averaged around $1.7 million, with its median value being -$11.8 million (2025).
  • Its Change in Cash has fluctuated over the past 5 years, first skyrocketed by 767202.07% in 2021, then plummeted by 29643.44% in 2024.
  • Barinthus Biotherapeutics' Change in Cash (Quarter) stood at -$19.8 million in 2021, then surged by 71.14% to -$5.7 million in 2022, then crashed by 218.57% to -$18.2 million in 2023, then soared by 134.57% to $6.3 million in 2024, then tumbled by 292.28% to -$12.1 million in 2025.
  • Its Change in Cash stands at -$12.1 million for Q3 2025, versus -$12.8 million for Q2 2025 and -$11.8 million for Q1 2025.